Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine as a ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Paintings by Ali Akbar Sadeqi are currently on view in an exhibition at Dastan Basement Gallery.  The exhibit will be running ...

A new Dutch book provides the first comprehensive account of how the artist’s work has been targeted by thieves ...

BRITS are being urged to stay at home and mask up when venturing outside after a “worrying” surge in norovirus cases. While ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $45 from $55 and keeps a Market Perform rating on the shares. The firm cites the ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

The Trump administration has intervened in the release of important studies on the bird flu, as an outbreak escalates across ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...